hackint0sh/New-Dataset huggingface dataset:
Outcomes Assessor. Study and control groups data were coded into the SPSS programme as group one and group two. Analysis of data was done by an independent statistician. The statistician has no information about which group the patients belong to. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 78 type: ACTUAL name: First mobilization protocol measure: Anxiety evaluated using the Trait Anxiety Inventory (Trait Anxiety Inventory, TAI) measure: Kinesiophobia evaluated using the Tampa Kinesiophobia Scale measure: Anxiety evaluated using the State Anxiety Inventory (State Anxiety Inventory, SAI) measure: Symptoms evaluated using the Numerical Rating Scale for Symptoms Related to First Mobilization sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gazi University Health Research and Application Center city: Ankara zip: 06560 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06268873 id: D6972C00003 briefTitle: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. overallStatus: RECRUITING date: 2024-03-29 date: 2027-12-10 date: 2027-12-10 date: 2024-02-20 date: 2024-04-25 name: AstraZeneca class: INDUSTRY briefSummary: The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone.
nctId: NCT06268860 id: 20220015 briefTitle: A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants overallStatus: RECRUITING date: 2024-02-15 date: 2024-08-29 date: 2024-08-29 date: 2024-02-20 date: 2024-04-12 name: Amgen class: INDUSTRY briefSummary: The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants. conditions: Atopic Dermatitis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 230 type: ESTIMATED name: Rocatinlimab vial injection name: Rocatinlimab prefilled syringe measure: Maximum Observed Serum Concentration (Cmax) of Rocatinlimab measure: Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab measure: AUC From Time Zero to Infinity (AUCinf) of Rocatinlimab measure: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE) measure: Number of Participants Experiencing Serious Adverse Events (SAE) measure: Number of Participants Positive to Anti-rocatinlimab Antibody sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fortrea Clinical Research Unit - Daytona Beach status: RECRUITING city: Daytona Beach state: Florida zip: 32117-5116 country: United States lat: 29.21081 lon: -81.02283 facility: Fortrea Clinical Research Unit - Dallas status: RECRUITING city: Dallas state: Texas zip: 75247-4968 country: United States lat: 32.78306 lon: -96.80667 facility: Fortrea Clinical Research Unit Limited - Leeds status: RECRUITING city: Leeds state: LDS zip: LS2 9LH country: United Kingdom lat: 53.79648 lon: -1.54785 hasResults: False
nctId: NCT06268847 id: DERMATIDYSS briefTitle: Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms overallStatus: RECRUITING date: 2024-01-09 date: 2024-06-18 date: 2024-06-18 date: 2024-02-20 date: 2024-02-20 name: Abyss Ingredients class: INDUSTRY name: Eurofins briefSummary: This interventional, double-blind, randomized, placebo-controlled study aims to evaluate the effect of a marine by-product hydrolysate supplementation on the reduction of atopic dermatitis symptoms. conditions: Atopic Dermatitis conditions: Eczema studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 108 type: ESTIMATED name: Placebo name: ACT01 name: ACT02 measure: SCORAD (SCORing Atopic Dermatitis) measure: EASI (Eczema Area and Severity Index) measure: Investigator Global Assessment scale measure: Corneometer measure: Tewameter measure: Quality of Life Index - Perceived Stress measure: Participant's Satisfaction sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Eurofins status: RECRUITING city: Barcelona zip: 08013 country: Spain name: Jessica Zumaquero role: CONTACT phone: +34 932 85 14 46 phoneExt: 1110 email: JessicaZumaquero@eurofins.com lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06268834 id: ZonulinPPI briefTitle: Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome overallStatus: COMPLETED date: 2023-10-04 date: 2023-12-31 date: 2023-12-31 date: 2024-02-20 date: 2024-02-20 name: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital class: OTHER briefSummary: Our study aims to investigate the effect of bacterial overgrowth induced by long-term PPI use on zonulin levels. conditions: Proton Pump Inhibitor Adverse Reaction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment primaryPurpose: PREVENTION masking: NONE count: 75 type: ACTUAL name: Blood for zonulin level was drawn from the group. measure: Zonulin levels in long-term proton pump inhibitor users sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06268821 id: ADC-UK-PMS-23059 briefTitle: Effect on HbA1c of the Initiation of CGM in Adults With Type 2 Diabetes Treated With Basal Insulin in Finland overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-01 date: 2025-01 date: 2024-02-20 date: 2024-02-20 name: Abbott Diabetes Care class: INDUSTRY briefSummary: The goal of this clinical study is to determine the impact of starting the use of the FreeStyle Libre 2 glucose monitoring system, over a three month period, on HbA1c in adults with type 2 diabetes treated with a basal insulin regimen. conditions: Type 2 Diabetes Treated With Insulin studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 82 type: ESTIMATED name: FreeStyle Libre 2 Flash Glucose Monitoring System measure: HbA1c measure: Time in range (TIR) measure: Time above range (TAR) measure: Time below range (TBR) measure: Frequency of hypoglycaemia events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pihlajalinna Jämsä, Välikatu 1, city: Jämsä zip: 42100 country: Finland name: Henri Honka, MD, PhD role: CONTACT lat: 61.8642 lon: 25.19002 facility: Pihlajalinna Koskiklinikka, Hatanpäänvaltatie 1, city: Tampere zip: 33100 country: Finland name: Elina Pimiä, MD role: CONTACT lat: 61.49911 lon: 23.78712 hasResults: False
nctId: NCT06268808 id: ADC-UK-PMS-23058 briefTitle: Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-12 date: 2024-12 date: 2024-02-20 date: 2024-02-20 name: Abbott Diabetes Care class: INDUSTRY briefSummary: The goal of this clinical study is to determine the impact of starting the use of the FreeStyle Libre 2 glucose monitoring system, over a three month period, on HbA1c in adults with type 2 diabetes treated with a basal insulin regimen. conditions: Type 2 Diabetes Treated With Insulin studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 82 type: ESTIMATED name: FreeStyle Libre 2 Flash Glucose Monitoring System measure: HbA1c measure: Time in range (TIR) measure: Time above range (TAR) measure: Time below range (TBR) measure: Frequency of hypoglycaemia events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari city: Bari country: Italy name: Francesco Giorgino role: CONTACT lat: 41.11148 lon: 16.8554 facility: Università degli Studi di Catania, Ospedale Garibaldi-Nesima, U.O. Endocrinologia city: Catania country: Italy name: Lucia Frittitta role: CONTACT lat: 37.49223 lon: 15.07041 facility: Università degli Studi di Catania, Ospedale Garibaldi-Nesima, U.O.C. Medicina Interna city: Catania country: Italy name: Salvatore Piro role: CONTACT lat: 37.49223 lon: 15.07041 facility: Azienda Ospedaliera - Università di Padova city: Padova country: Italy name: Gian Paolo Fadini role: CONTACT lat: 45.40797 lon: 11.88586 facility: Azienda Ospedaliero-Universitaria di Parma city: Parma country: Italy name: Riccardo Bonadonna role: CONTACT lat: 44.79935 lon: 10.32618 facility: La Sapienza Università di Roma, AOU Policlinico Umberto I city: Rome country: Italy name: Raffaella Buzzetti role: CONTACT lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06268795 id: BASE briefTitle: A Diagnostic Test Accuracy Study Comparing Biopsy to Aspiration in Shoulder and Elbow Arthroplasty Revision Surgery (BASE Study) overallStatus: RECRUITING date: 2024-03-20 date: 2028-09-01 date: 2028-09-01 date: 2024-02-20 date: 2024-04-24 name: Wrightington, Wigan and Leigh NHS Foundation Trust class: OTHER briefSummary: The aim of this study is to compare the diagnostic accuracy of percutaneous aspiration against open biopsy, using microbiological and histological methods, for the detection of shoulder and elbow periprosthetic joint infection (PJI). This is to establish the utility of pre-operative joint aspiration in the treatment pathway for shoulder and elbow PJI. conditions: Periprosthetic Joint Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 244 type: ESTIMATED measure: Comparison of diagnostic accuracy measure: Culture analysis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wrightington Wigan & Leigh Teaching Hospitals NHS Foundation Trust status: RECRUITING city: Wigan state: Lancashire zip: WN6 9EP country: United Kingdom name: Zaid Z Hamoodi role: CONTACT email: zaid.hamoodi@nhs.net lat: 53.54295 lon: -2.63705 hasResults: False
nctId: NCT06268782 id: 1204202118 briefTitle: The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women overallStatus: COMPLETED date: 2021-09-21 date: 2023-01-24 date: 2023-09-19 date: 2024-02-20 date: 2024-02-22 name: University of Turku class: OTHER name: Finnish Cultural Foundation briefSummary: The aim of this quasi-experimental study was to assess the effectiveness of a 6-week online exercise program on self-assessed quality of life (QoL), physical activity (PA), and dysfunctions of pelvic floor muscles of postpartum women immediately and 6 months after the online intervention. The data were collected with e-questionnaires. The data collection started in September 2021 and ended in September 2023. conditions: Quality of Life conditions: Physical Activity conditions: Urinary Incontinence conditions: Pelvic Organ Prolapse studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 308 type: ACTUAL name: Rehabilitate your core measure: Quality of Life measure: Physical activity measure: Urinary incontinence measure: Pelvic organ prolapse sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Nursing Science, Faculty of Medicine, University of Turku city: Turku zip: 20014 country: Finland lat: 60.45148 lon: 22.26869 hasResults: False
nctId: NCT06268756 id: 2023_RIPH_020_RESANXIEST briefTitle: Fear of Other's Judgment, Self-esteem and Use of Social Networks Among Students acronym: RESANXIEST overallStatus: RECRUITING date: 2024-02-07 date: 2024-04-07 date: 2024-06-07 date: 2024-02-20 date: 2024-02-20 name: Université de Reims Champagne-Ardenne class: OTHER briefSummary: Fear of being judged negatively by others can lead to avoidance of social situations or even social isolation. If the intensity of this fear is excessive and results in significant impairment of functioning or significant suffering, the subject may suffer from social anxiety.
The considerable growth of social networks in a decade has led to the emergence of new behaviors among young people. Individuals spend on average 2 hours and 27 minutes per day with differences in usage: time spent, social network used, function sought. The use of these networks may be reasonable and moderate but may also be excessive and abusive (Amnon, 2014). Some authors even talk about addiction or dependence on social networks (Perales and Billieux, 2020) even if the existence of this disorder is not consensus.
People who fear being judged negatively by others may be more at risk of misuse of social networks. Indeed, the use of social networks would compensate for their existing problems (Kardefelt-Winther, 2014) and would thus be a new emotional management strategy. It would also reduce dreaded social situations such as face-to-face exchanges (Weidman and Rodebaugh, 2012; Yen and Ko, 2012). Self-esteem is defined as a subjective judgment of oneself in relation to one's values and vision of the real and ideal self (Rosenberg. 1979). The greater the gap between the vision of the real self and the ideal self, the lower the self-esteem. conditions: Self-esteem studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 500 type: ESTIMATED name: Data collection measure: Rosenberg Self-esteem Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ufr Medecine Urca status: RECRUITING city: Reims zip: 51100 country: France name: Coralie Barbe role: CONTACT phone: 326913665 phoneExt: +33 email: coralie.barbe1@univ-reims.fr lat: 49.25 lon: 4.03333 facility: Université de Reims Champagne Ardenne status: RECRUITING city: Reims zip: 51100 country: France name: CURRS CURRS role: CONTACT phone: 0326918822 email: currs@univ-reims.fr lat: 49.25 lon: 4.03333 hasResults: False
nctId: NCT06268743 id: 2023-114 briefTitle: Effects of a Combined Exercise Intervention on the Gut Microbiome of People With Type 2 Diabetes acronym: GUTFIT overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-08 date: 2026-08 date: 2024-02-20 date: 2024-03-01 name: University of New Brunswick class: OTHER name: Laval University briefSummary: The goal of this experimental trial is to learn about the changes in bacterial diversity in individuals with type 2 diabetes who perform endurance and strength training at different intensities.
Researchers will compare the moderate-intensity and high-intensity exercise groups for differences in glycemia and bacterial diversity. conditions: Type 2 Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel group, single blinded, randomized trial primaryPurpose: PREVENTION masking: SINGLE whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: High intensity name: Moderate intensity measure: Glycemic control through glycated hemoglobin measure: Gut microbiome diversity through 16S ribosomal RNA genes sex: ALL minimumAge: 19 Years maximumAge: 64 Years stdAges: ADULT hasResults: False
nctId: NCT06268730 id: 23-2437 briefTitle: Effects of SinuSonic on Psychological and Physical Well-Being overallStatus: RECRUITING date: 2024-03-28 date: 2024-07 date: 2024-07 date: 2024-02-20 date: 2024-03-29 name: University of North Carolina, Chapel Hill class: OTHER name: Healthy Humming, LLC briefSummary: The goal of this clinical trial is to evaluate the effects of using the SinuSonic on psychological and physical well-being in adults who have nasal/sinus congestion.
Participants will be asked to complete self-report measures of physical health, mental health and autonomic regulation before using SinuSonic (i.e., baseline research session) and after 5 weeks of directed use (post-intervention). Demographic information and adverse experiences will be documented during the baseline research session. Participants will be asked to document (weekly) current nasal symptoms and SinuSonic usage. conditions: Nasal Congestion and Inflammations conditions: Sinus Congestion Chronic studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All participants will follow the same procedures. primaryPurpose: BASIC_SCIENCE masking: NONE count: 50 type: ESTIMATED name: SinuSonic measure: Change in the Anxiety Subscale of the Hospital Anxiety and Depression Scale measure: Change in the Depression Subscale of the Hospital Anxiety and Depression Scale measure: Change in the Body Perception Questionnaire measure: Change in the Total Nasal Symptom Score measure: Change in the Patient Global Impression of Change measure: Adverse Traumatic Experiences Survey at Baseline measure: Short Form Health Survey (SF-20) at Baseline sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of North Carolina at Chapel Hill status: RECRUITING city: Chapel Hill state: North Carolina zip: 27599-7160 country: United States name: Keri J Heilman, PhD role: CONTACT email: keri_heilman@med.unc.edu name: Keri J Heilman, PhD role: PRINCIPAL_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06268717 id: 23-0316 briefTitle: GI Alpha-Gal Study overallStatus: RECRUITING date: 2023-10-17 date: 2024-10-17 date: 2025-10-17 date: 2024-02-20 date: 2024-02-20 name: University of North Carolina, Chapel Hill class: OTHER name: Revivicor, Inc briefSummary: This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms. conditions: Alpha-Gal Syndrome conditions: Irritable Bowel Syndrome conditions: Diarrhea conditions: Abdominal Pain conditions: Vomiting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Double-blind crossover. Each participant will be randomized to undergo two double-blind food challenges with at least a 10-day washout period between the challenges. One food challenge will contain pork meat containing alpha-gal sugar; one challenge will contain pork meat without alpha-gal sugar. primaryPurpose: OTHER masking: QUADRUPLE maskingDescription: The principal investigator and clinical research coordinators will be blinded to the challenges during the course of the study. The metabolic kitchen and a delegated research staff member will be unblinded. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Ground pork containing alpha-gal name: Pork meat not containing alpha-gal measure: Allergic reaction (food challenge positive) measure: No allergic reaction (food challenge negative) measure: Lactulose excretion measure: C13 mannitol excretion measure: Basophil activation threshold response at timepoint 0 measure: Basophil activation threshold response at 2 hours measure: Basophil activation threshold response at 4 hours measure: Basophil activation threshold response at 6 hours measure: Serum tryptase at timepoint 0 measure: Serum tryptase at 2 hours measure: Serum tryptase at 4 hours measure: Serum tryptase at 6 hours measure: Mast cell count on stomach biopsies (per high powered field (hpf)) measure: Mast cell count on small bowel biopsies (per high powered field (hpf)) measure: Eosinophil cell count on stomach biopsies (per high powered field (hpf)) measure: Eosinophil cell count on small bowel biopsies (per high powered field (hpf)) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of North Carolina at Chapel Hill status: RECRUITING city: Chapel Hill state: North Carolina zip: 27599 country: United States name: Sarah McGill, MD role: CONTACT phone: 919-966-7047 email: mcgills@email.unc.edu name: Sarah McGill, MD role: PRINCIPAL_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06268704 id: UNM HRRC #23-503 briefTitle: Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection overallStatus: RECRUITING date: 2024-03-27 date: 2025-01-01 date: 2025-05-01 date: 2024-02-20 date: 2024-03-29 name: University of New Mexico class: OTHER briefSummary: This study will compare two different corticosteroids (dexamethasone and methylprednisolone) for use in sacroiliac joint injections to treat SI joint pain. conditions: Sacroiliac Joint Dysfunction conditions: Sacro-Iliac Spondylosis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 230 type: ESTIMATED name: Dexamethasone name: Methylprednisolone name: 2% Lidocaine HCl Injection measure: Pain using Numeric Pain Rating Score sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of New Mexico Hospital status: RECRUITING city: Albuquerque state: New Mexico zip: 87131 country: United States name: Mark W Shilling, BS role: CONTACT phone: 505-925-7599 email: mwshilling@salud.unm.edu lat: 35.08449 lon: -106.65114 hasResults: False
nctId: NCT06268691 id: ProjectCOLOMBIA-ZMG.U-Freiburg briefTitle: Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating overallStatus: COMPLETED date: 2019-02-04 date: 2019-09-02 date: 2023-07-31 date: 2024-02-20 date: 2024-02-20 name: Rocio Cardenas Sanchez class: OTHER name: Göteborg University name: Instituto Nacional de Salud, Colombia name: Instituto Departamental de Salud de Norte de Santander name: Universidad Francisco de Paula de Santander briefSummary: Effective control of Aedes aegypti mosquitoes in breeding sites with high reproductive rates could have a major impact on reducing arbovirosis in endemic communities. The application of a safe, effective, low cost and sustained insecticide coating (IC) could be an affordable response to dengue for local health services. Therefore, a cluster randomised trial for the application of a new vector control tool (insecticidal coating of water containers) was conducted in the metropolitan area of Cúcuta, Colombia. The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.07%) in suspension, without interaction between them, development by INESFLY®, Spain.
The Baseline study to characterise the study clusters from entomological, epidemiological and socio-economic approaches was carried out in 2019-2020. The IC application phase in the intervention arm was carried out between Nov-2021 and Jan-2022, with the respective monitoring of the safety of IC use. This was followed by entomological monitoring. Finally, the 9-month post-intervention evaluation. Epidemiological data were obtained from the National Public Health Surveillance System - SIVIGILA.